EFFICACY plus SAFETY OF PALBOCICLIB (P) IN PATIENTS (PTS) ≤50 Y WITH HORMONE RECEPTOR- POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP ANALYSIS OF 2 RANDOMIZED PHASE 3 STUDIES

被引：1
|
作者：
Cristofanilli, Massimo [5 ]
Harbeck, Nadia [1 ]
Rugo, Hope [14 ]
Castrellon, Aurelio [4 ]
Joy, Anyl A. [12 ]
Verma, Sunil [13 ]
Im, Seock-Ah [11 ]
Iyer, Shrividya [7 ]
Puyana, Kathy [8 ]
Gauthier, Eric [6 ]
Huang, Xin [9 ]
Bartlett, Cynthia Huang [10 ]
Loibl, Sibylle [3 ]
Finn, Richard S. [2 ]
机构：
[1] Brustzentrum Univ Muenchen LMU, Dept Obstet & Gynecol, Munich, Germany
[2] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Santa Monica, CA USA
[3] German Breast Grp, Neu Isenburg, Germany
[4] Mem Healthcare Syst, Breast Canc Ctr, Hollywood, CA USA
[5] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA
[6] Pfizer Inc, Global Prod Dev, San Francisco, CA USA
[7] Pfizer Oncol, Patient & Hlth Impact, New York, NY USA
[8] Pfizer Oncol, Global Product Dev, Cambridge, MA USA
[9] Pfizer Oncol, Global Prod Dev, San Diego, CA USA
[10] Pfizer Oncol, Global Med Affairs, Collegeville, PA USA
[11] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea
[12] Univ Alberta, Dept Oncol, Edmonton, AB, Canada
[13] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[14] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
BREAST | 2018年 / 41卷
关键词：
D O I：
10.1016/j.breast.2018.08.033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OR52
引用
收藏
页码：S11 / S12
页数：2
相关论文
共 50 条
  • [1] Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies (vol 41s1, pg s11, 2018)
    Cristofanilli, Massimo
    Harbeck, Nadia
    Rugo, Hope S.
    Castrellon, Aurelio
    Joy, Anil Abraham
    Verma, Sunil
    Im, Seock-Ah
    Iyer, Shrividya
    Theall, Kathy Puyana
    Gauthier, Eric
    Huang, Xin
    Bartlett, Cynthia Huang
    Loibl, Sibylle
    Finn, Richard S.
    [J]. BREAST, 2020, 49 : 131 - 131
  • [2] Ribociclib plus letrozole in premenopausal patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Razeq, Hikmat Abdel
    Cottu, Paul
    Ring, Alistair
    De laurentiis, Michelino
    Lu, Janice
    Azim, Hamdy
    Zamagni, Claudio
    Zhou, Katie
    Wu, Jiwen
    Menon-Singh, Lakshmi
    Martin, Miguel
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [3] Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor. positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.
    Verma, Sunil
    Im, Seock-Ah
    Ro, Jungsil
    Bondarenko, Igor
    Masuda, Norikazu
    Colleoni, Marco
    Verma, Shailendra
    Schnell, Patrick
    Bananis, Eustratios
    Lu, Dongrui
    Ettl, Johannes
    Cristofanilli, Massimo
    Rugo, Hope S.
    Finn, Richard S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3
    Cristofanilli, M.
    Slamon, D. J.
    Ro, J.
    Bondarenko, I.
    Im, S-A.
    Masuda, N.
    Colleoni, M.
    DeMichele, A.
    Loi, S.
    Verma, S.
    Iwata, H.
    Harbeck, N.
    Loibl, S.
    Andre, F.
    Theall, K. Puyana
    Huang, X.
    Giorgetti, C.
    Bartlett, C. Huang
    Turner, N. C.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [5] Palbociclib exposure-response analyses in the treatment of hormone-receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC)
    Zheng, Jenny
    Yu, Yanke
    Durairaj, Chandrasekar
    Amantea, Michael
    Dieras, Veronique
    Finn, Richard
    Wang, Diane
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [6] Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer (ABC): an age-specific subgroup analysis of the phase 3, MONARCH 2 and 3 trials
    Grischke, E-M
    Goetz, M. P.
    Okera, M.
    Wildiers, H.
    Campone, M.
    Manso, L.
    Andre, V. A. M.
    Chong, A. L.
    San Antonio, B.
    Toi, M.
    Sledge, Jr G. W.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 162 - 163
  • [7] Efficacy and safety of palbociclib (PAL) in patients (pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with preexisting conditions: A post hoc analysis of PALOMA-2
    Gelmon, Karen
    Walshe, Janice M.
    Mahtani, Reshma
    Joy, Anil A.
    Karuturi, Meghan
    Neven, Patrick
    Lu, Dongrui Ray
    Kim, Sindy
    Schnell, Patrick
    Bananis, Eustratios
    Schwartzberg, Lee
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [8] Impact of prior treatment on palbociclib plus letrozole (P plus L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis
    Finn, R. S.
    Gelmon, K. A.
    Ettl, J.
    Asselah, J.
    Castrellon, A.
    Ruiz Simon, A.
    Joy, A. A.
    Lu, D.
    Gauthier, E. R.
    Mori, A.
    Rugo, H. S.
    Dieras, V.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [9] Ribociclib (RIB) plus fulvestrant (FUL) in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses
    Neven, P.
    Petrakova, K.
    Bianchi, G. V.
    Merino, L. De la Cruz
    Jerusalem, G.
    Beck, J. T.
    Sonke, G. S.
    Chia, S.
    Brucker, S.
    Wang, Y.
    He, W.
    Lorenc, K. Rodriguez
    Su, F.
    Im, S-A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 113 - +
  • [10] Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2-ABC) participating in the PALOMA trials
    Isaacs, Claudine
    Mahtani, Reshma
    Lynce, Filipa
    Sleckman, Bethany
    Castrellon, Aurelio
    Kalmadi, Sujith
    Theall, Kathy Puyana
    Huang, Xin
    Bananis, Eustratios
    Rugo, Hope S.
    [J]. CANCER RESEARCH, 2022, 82 (04)
12345